Acuta Capital Partners, LLC Avadel Pharmaceuticals PLC Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $620,600 - $4.03 Million	-580,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $103,679 - $157,418	18,989 Added 3.38%	580,000 $3.96 Million
Q2 2021 Aug 16, 2021	SELL	$6.73 - $9.05 $3.59 Million - $4.83 Million	-533,989 Reduced 48.77%	561,011 $3.78 Million
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $2.58 Million - $3.93 Million	389,782 Added 55.27%	1,095,000 $9.9 Million
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $5.26 Million - $9.4 Million	-1,047,000 Reduced 59.75%	705,218 $3.55 Million
Q2 2020 Aug 14, 2020	SELL	$7.25 - $11.75 $6.68 Million - $10.8 Million	-921,500 Reduced 34.47%	1,752,218 $14.2 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $4.26 Million - $11.2 Million	1,048,718 Added 64.54%	2,673,718 $20.9 Million
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $5.43 Million - $12.5 Million	1,625,000 New	1,625,000 $12.3 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.